stockrowZymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) EBITDA
Zymeworks Inc.'s EBITDA for fiscal 2025 was −$81.4M, compared with −$125.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$146.1M. Over the past ten years it has ranged from −$206.1M (fiscal 2021) to $137.8M (fiscal 2022); the current reading is higher than 55% of that period. Zymeworks Inc. ranks 467th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$81.4M | — |
| FY2024 | −$125.9M | — |
| FY2023 | −$120.7M | — |
| FY2022 | $137.8M | — |
| FY2021 | −$206.1M | — |
| FY2020 | −$177.2M | — |
| FY2019 | −$144.0M | — |
| FY2018 | −$29.7M | — |
| FY2017 | −$6.3M | — |
| FY2016 | −$36.8M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$40.1M | — |
| Mar 2026 | −$44.2M | — |
| Dec 2025 | −$42.1M | — |
| Sep 2025 | −$19.5M | — |
| 38 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $163.4M |
| VCEL Vericel Corporation compare | $31.3M |
| SEPN Septerna, Inc. compare | −$41.9M |
| COAG Hemab Therapeutics Holdings, Inc. compare | −$82.0M |
| ZYME Zymeworks Inc. | −$146.1M |
| IMNM Immunome, Inc. compare | −$268.3M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$416.8M |
| VERA Vera Therapeutics, Inc. compare | −$417.0M |
| BHVN Biohaven Ltd. compare | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ZYME
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement